BioSpace News Archive

ABVC BioPharma, Inc. announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc.

Bexion Pharmaceuticals, Inc. announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA.

Moleculin Biotech, Inc. today announced positive preclinical data regarding the Company’s next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.

Inogen, Inc. today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024.

Global High-Performance Liquid Chromatography Market is valued at US$ 5.16 Bn in 2023, and it is expected to reach US$ 7.30 Bn by 2031, with a CAGR of 4.43% during the forecast period of 2024-2031.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard®, in the largest real-world multi-center study presented at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.

Raydiant Oximetry, Inc. announces that the United States Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for an Early Feasibility Study (EFS) of pregnant women during labor and delivery.

According to Vision Research Reports, the global atopic dermatitis clinical trials market size was accounted at USD 2.37 billion in 2023 and it is expected to increase around USD 6.81 billion by 2033, poised to grow at a CAGR of 11.14% from 2024 to 2033.

Opna Bio presented promising preclinical data in two programs, OPN-6602, a dual EP300/CBP inhibitor in multiple myeloma, and OPN-9840, an oral, non-covalent TEAD inhibitor in malignant mesothelioma and metastatic melanoma.